Zosano Pharma Corp

Zosano Pharma — Investor Presentation (January 2021)

37 slides from Zosano Pharma's investor presentation, Jan 6, 2021

  1. Slide 1: Corporate Presentation January 2021

    Corporate Presentation January 2021 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements regarding Zosano’s technology and product candidates, including QtryptaTM and C213, and other future events and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "coul

  3. Slide 3: Zosano Pharma: Working to Transform How Drugs Are Delivered

    Zosano Pharma: Working to Transform How Drugs Are Delivered Significant Clinical Evidence Versatile Platform Differentiated Technology OUR MISSION Advancing Patient Care and Transforming Patient Lives Through Therapies Developed Utilizing Our Proprietary Delivery Platform OUR FOCUS Late Stage Clinic

  4. Slide 4: Executive Summary and Recent Developments

    Executive Summary and Recent Developments Transformative Delivery Platform Addressing Significant Unmet Needs in Migraine Clinically Significant Phase 3 Results Key Developments Migraine is Ranked Globally as the Seventh Most Disabling Disease1 Migraine Impacts approximately 37 Million People in the

  5. Slide 5: Zosano's Transdermal Drug Delivery

    Zosano’s Transdermal Drug Delivery Novel & Proprietary Transdermal patch with drug-coated microneedle array Designed to be Rapid & Consistent Designed for rapid and consistent absorption of drugs into capillary bed Designed to Minimize Application Site Sensation Shallow penetration designed to minim

  6. Slide 6: Qtrypta Designed for Optimization of Therapy Delivery

    Qtrypta™ Designed for Optimization of Therapy Delivery

  7. Slide 7: Designed to Address Unmet Needs in Migraine

    DESIGNED TO ADDRESS UNMET NEEDS IN MIGRAINE

  8. Slide 8: Migraine is Highly Prevalent, Debilitating and Costly

    Migraine is Highly Prevalent, Debilitating and Costly Prevalent1 3rd Most Prevalent Disorder in the World Impacts ~25% of U.S. Households Occurs in 12% of U.S. Population 90% Unable to Function Normally 1.2 MM ER Visits per Year 25% of women experience 4+ Migraines/Month Attacks Last 4-72 Hours Cost

  9. Slide 9: Patients Want Fast And Complete Pain Relief That Lasts

    Patients Want Fast And Complete Pain Relief That Lasts 74% of Sufferers 38% of Sufferers 49% of Sufferers 65% of Sufferers Reported Inadequate Treatment Response Reported Rapid Headache Onset Reported Inadequate 2 Hour Pain Freedom Reported Recurrence of Headache Within 24 Hours Lipton et al. Unmet

  10. Slide 10: Triptans Are and Will Remain the Standard of Care

    Triptans Are and Will Remain the Standard of Care “…and use migraine-specific agents (triptans), for moderate or severe attacks…” treat early after the onset of a migraine attack choose a non-oral route of administration for selected patients account for tolerability and safety issues 1. The America

  11. Slide 11: Qtrypta Clinical Results From Phase 2/3 ZOTRIP Study

    Qtrypta Clinical Results From Phase 2/3 ZOTRIP Study 15 Mins Results 23% of Patients Achieved Pain Relief Efficacy Results Activity 81% 42% Observed Peak Plasma Concentration Reported Pain Freedom at 2 Hours 78% Reported Pain Relief at 24 Hours Reported Pain Relief at 2 Hours Spierings ELH et al. Ra

  12. Slide 12: Clinically Significant Results on Pain Freedom and MBS in Phase 2/3 Study

    Clinically Significant Results on Pain Freedom and MBS in Phase 2/3 Study p=<0.0001 TG = 27.2 p=<0.0009 TG = 25.4 Successful Achievement of Co-Primary Endpoints Spierings ELH et al. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zo

  13. Slide 13: Qtrypta Showed Rapid and Sustained Effect With One Dose

    Qtrypta Showed Rapid and Sustained Effect With One Dose * ** ** ** ** ** ** ** Spierings ELH et al. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. Cephalalgia 2018 Feb;38(2):215-224

  14. Slide 14: Early Separation From Placebo Observed Within 15 Minutes

    * ** ** ** ** ** ** Spierings ELH et al. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. Cephalalgia 2018 Feb;38(2):215-224. *p=<0.05 **p=0.01 Early Separation From Placebo Observed

  15. Slide 15: Positive Results Seen Even in the Most Difficult Migraine Types

    Positive Results Seen Even in the Most Difficult Migraine Types Migraine On Awakening 44% 69% Reported Pain Freedom at 2 Hours Migraine With Severe Pain Reported Pain Relief at 2 Hours 44% 33% Migraine With Nausea Reported Pain Freedom at 2 Hours Delayed Treatment > 2 Hours Reported Pain Freedom at

  16. Slide 16: Long Term Safety Study Showed Consistent Response

    Long Term Safety Study Showed Consistent Response Endpoint ZOTRIP Pivotal Study (Single Dose) Open-Label Long-Term Placebo (N = 77) M207 3.8 mg (N = 82) M207 3.8 mg (N = 5,617 attacks) Pain Freedom at 2 hours 14% 42% 44% Pain Relief at 2 hours 57% 81% 81% Sustained Pain Freedom 2-24 hour 10% 32% 38%

  17. Slide 17: Qtrypta was Well Tolerated in the Long-Term Safety Study

    Qtrypta was Well Tolerated in the Long-Term Safety Study Most Common Adverse Events were Application Site Redness/Swelling. 95% were Mild 80% Resolved Within 48 hours Less than 2% of Patients Reported Neurological Triptan-like Side Effects Such as Dizziness and Paresthesia. Spierings E.L.H., et al.

  18. Slide 18: Favorable Migraine-ACT Responses From the Long-Term Safety Trial

    Favorable Migraine-ACT Responses From the Long-Term Safety Trial Proportion of Participants Who Answered “Yes” at 48 Weeks Migraine-ACT questionnaire a standardized evaluation completed by patients to assess the effectiveness of a patient’s acute treatment of migraine therapy Does the Headache Pain

  19. Slide 19: Commercial Strategy

    COMMERCIAL STRATEGY Copyright© 2021 Zosano Pharma inc, | Confident

  20. Slide 20: Zosano/EVERSANA Partnership Agreement

    Zosano/EVERSANA Partnership Agreement Approximately $250MM Expected Commercialization Budget over 5 Year Term Comprehensive Commercialization Services

  21. Slide 21: 8MM Migraine Patients Represent a Large, Focused Opportunity

    8MM Migraine Patients Represent a Large, Focused Opportunity 37 Million Suffer From Migraine ~8 MM Patients Account for ~60% of All Monthly Headache Days Resulting in >150 Million Migraine-Days 29 million with 0 - 4 migraines/ month 5 – 9 10 - 14 15+ # Specialists Treating ~ 60m Headache Days ~35m 4

  22. Slide 22: Patients Continue to Suffer Even with New Market Entrants

    Patients Continue to Suffer Even with New Market Entrants Neurologists Have a Difficult-To-Treat Population 67% Of Physicians’ Patients are on Preventive Therapy Experiencing > 4 Headaches Monthly 300+ Migraine Patients Treated Monthly (Avg.) 51% of These Patients Have High Unmet Needs AND… Strongly

  23. Slide 23: Physician Market Research: Neurologists Strongly Agree that…

    Physician Market Research: Neurologists Strongly Agree that… 79% Still an UNMET NEED in the acute setting even in patients that respond to preventive therapy 79% Patients with morning migraine need a therapy with FAST ONSET and high success of PAIN RELIEF Using a NON-ORAL therapy in the difficult to

  24. Slide 24: Physician Market Research: Strong Positive Reaction to Qtrypta's Potential Product Profile

    Physician Market Research: Strong Positive Reaction to Qtrypta’s Potential Product Profile Differentiated Potential Product Attributes Key Drivers for HCP Adoption ZS Associates May 2020 Market Research: Insights drawn from n=19 Neurologists, n=4 NP/PAs, n=11 PCPs, and n=5 KOLs Positive Impression o

  25. Slide 25: Survey Data Suggest Product Profile Could Be Well Positioned for Adoption

    Survey Data Suggest Product Profile Could Be Well Positioned for Adoption and May Be More Favorable Than New Market Entrants 17% - 24% Potential Share of Acute Treatments for Migraine after Product X Launch* 7%- 16% Ubrogepant 7%- 15% 7%- 16% Rimegepant Lasmiditan ZS Associates May 2020 Market Resea

  26. Slide 26: Payer Feedback on Market Access for Product X, if Approved

    Payer Feedback on Market Access for Product X, if Approved Recognition that Migraine Patients May Need Non-oral Treatment Options Speed of Onset and Sustained Response Noted as Positives Likely Formulary Placement Will be Tier 3 or Non-preferred After Failure of Two Generic Triptans Formulary Placem

  27. Slide 27: Strong Market Opportunity with a Compelling Value Proposition

    Strong Market Opportunity with a Compelling Value Proposition Large and Concentrated Marketplace Differentiated Clinical Profile Fast Onset of Action Significant Pain Freedom Lack of Recurrence Low Percentage of Triptan-like Side Effects Large Migraine Population Small Percentage of HCPs Treat the M

  28. Slide 28: Development of Qtrypta Timeline

    August: Commercialization Agreement with EVERSANA October: CRL from FDA December: Type A meeting Request Submitted to FDA December: Ended Enrollment in Phase 2/3 Cluster Study Development of Qtrypta June: 1st Subject Enrolled In Pivotal Study November: Completion of Enrollment 2016 2017 2020 2019 20

  29. Slide 29: Qtrypta Regulatory Update

    Qtrypta Regulatory Update Complete Response Letter Received October 20th, 2020 Differences in Zolmitriptan Exposures Observed Between Subjects Receiving Different Lots of Qtrypta in the Company’s Trials and Inadequate Pharmacokinetic Bridging Between the Lots Unexpected High Plasma Concentrations of

  30. Slide 30: Pipeline Expansion

    PIPELINE EXPANSION

  31. Slide 31: Leveraging Platform & Clinical Validation for Pipeline Expansion

    Leveraging Platform & Clinical Validation for Pipeline Expansion PRE-CLINICAL & CLINICAL PROOF-OF-CONCEPT STUDIES Initiated Three Collaborations in 2020 Mitsubishi Tanabe Assessing feasibility for undisclosed molecule Two Undisclosed Partners Assessing feasibility for undisclosed molecules Small Mol

  32. Slide 32: Partnering Opportunity for Development of Microneedle COVID-19 Vaccine

    Partnering Opportunity for Development of Microneedle COVID-19 Vaccine Ongoing Discussions with Potential COVID-19 Vaccine Co-developers Pursuing Non-dilutive Funding Opportunities for COVID -19 Programs Through Governmental Agencies Zosano Intends to Utilize Microneedle Technology to Develop a Sing

  33. Slide 33: Zosano Pharma Microneedle Array Drug Delivery System

    Zosano Pharma Microneedle Array Drug Delivery System Ideal solution for delivery of peptides, proteins and hydrophilic drugs First generation transdermal patches limited to hydrophobic molecules Low bioburden manufacturing and terminal sterilization mitigates need for aseptic manufacturing Room temp

  34. Slide 34: Dosage Flexibility Enabled by Formulation, Process and Design

    Dosage Flexibility Enabled by Formulation, Process and Design Formulation: Product formulation defines capability of coating on the microneedle substrate. Kept constant within a product family Process: Multiple dips increase coated amount per microneedle - once passes (& coating morphology) are set,

  35. Slide 35: Experienced Management Team

    Experienced Management Team Name Title Experience Steven Lo Chief Executive Officer Christine Matthews Chief Financial Officer Hayley Lewis Senior VP, Operations Don Kellerman VP, Clinical Development & Medical Affairs

  36. Slide 36: Board of Directors

    Board of Directors Name Title Experience John P. Walker Chairman, Zosano Pharma Steven Elms Managing Partner, Aisling Capital Linda Grais, MD, JD Director, Zosano Pharma Kenneth R. Greathouse Director, Zosano Pharma Joseph Hagan President and Chief Executive Officer, Regulus Therapeutics Inc. Steven

  37. Slide 37: Zosano Pharma

    ZOSANO P H A RM A

Zosano Pharma — Investor Presentation (January 2021) on 6ix